Publications by authors named "India L Neveras"
Article Synopsis
- Targeting PI3K/AKT/PTEN signalling offers promising therapy options for B-cell malignancies, particularly diffuse large B-cell lymphoma (DLBCL), despite challenges with existing PI3K inhibitors due to toxicity.
- The AKT inhibitor capivasertib, when used with the BCL-2 inhibitor venetoclax, shows significant therapeutic benefits in preclinical DLBCL models, inducing tumor cell death effectively.
- Adding rituximab to this drug combination enhances treatment outcomes, suggesting a potentially effective strategy for managing DLBCL patients who are resistant to standard therapies.
